REG - Eco Animal Health Gp - General Meeting Result

ECO Animal HealthAnnouncement

19/03/2024 09:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240319:nRSS4115Ha&default-theme=true

RNS Number : 4115H  Eco Animal Health Group PLC  19 March 2024

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

ECO Animal Health General meeting resolution passed

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that at its General Meeting held
earlier today ("GM") the special resolution proposed to the meeting to allow
the Company to make market purchases of its own shares was duly passed.

Proxy votes received in relation to the resolution were as follows:

 

 Resolution  For                                   Against         Withheld

                         %     Discretionary   %              %
 01          40,553,465  97.6  Nil             0   1,011,642  2.4  Nil

 

As previously announced the Company disposed of certain surplus freehold
properties and received net proceeds of £1,058,454. The board stated that it
intends to use the majority of these proceeds to advance the growth
aspirations of ECO. The Board also announced that it intends to use some of
the proceeds to purchase ordinary shares of the Company ("Ordinary Shares") in
the market to cover possible future vesting of employee share-based
incentives.  The authority conferred by this resolution will be used to
purchase a maximum of 270,000 Ordinary Shares in the market which is expected
to cost no more than £300,000.

In addition, in the remaining weeks before the close of the financial year
ending 31 March 2024, the Company intends to issue a trading update.

 

David Hallas, CEO of ECO, commented: "We are pleased to have received approval
from our shareholders enabling us to pursue this one-off share purchase. The
Board agreed that now is the optimal time to use proceeds from our recent
property disposals to purchase shares that will be used to satisfy share based
staff incentives."

 

-Ends-

 

 

 

For further information please contact:

 

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (CEO)

 Christopher Wilks (CFO)
 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Phil Davies

 Sam Butcher
 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Lydia Zychowska
 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans
 ICR Consilium (Financial PR)                                   020 3709 5700

 Mary-Jane Elliott                                              ecoanimalhealth@consilium-comms.com

                               (mailto:ecoanimalhealth@consilium-comms.com)
 Jessica Hodgson

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMQKCBBCBKKBND